Supplements and Compounds

Supplements and Compounds Library

Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.

Featured Library

View all library
Nature - npj AgingJul 20, 2026

Spermidine activates cellular renewal in aging

Spermidine, a naturally occurring polyamine synthesized by the body and present in foods, demonstrates protective effects against hallmark aging mechanisms including cellular senescence, mitochondrial dysfunction, and neurodegeneration. Evidence suggests spermidine activates autophagy and enhances stress resilience pathways, positioning it as a candidate metabolite for addressing age-related disease progression.

Wiley Aging CellOct 6, 2026

Fisetin Analogs Clear Senescent Cells Beyond Parent Compound

Phenotypic screening and structure-activity-guided design produced two fisetin-derived flavonoids, SR29384 and SR31133, that killed senescent cells more potently and more selectively than fisetin across multiple senescent cell types. In aged and progeroid mice, both compounds lowered tissue senescence burden and improved physical function and other healthspan measures. Mechanistic work points to PARP1, CDK2, and possibly BCL-xL as the pathways driving selective apoptosis in senescent cells.

The Lancet Healthy LongevityJul 30, 2026

Metformin's aging mechanisms: promise and clinical translation gaps

Metformin's effects on aging pathways—mTOR signaling, mitochondrial function, senescent cells, and microbiome modulation—have generated substantial interest in gerontology. Observable associations with reduced age-related disease incidence in humans warrant scrutiny of actual clinical benefit before adoption as a preventive strategy in aging populations.

Longevity.TechnologyOct 26, 2026

Tirzepatide Doubles Glycemic Target Rates in English Records

Retrospective primary-care data from England presented at EASD 2026 found that adults with type 2 diabetes starting tirzepatide reached an HbA1c below 6.5% at roughly twice the rate of those on injectable or oral semaglutide (46.3% versus 20.6% and 23.8%) over 12 months. Weight loss of at least 15% occurred in 24.1% of tirzepatide patients compared with 9.1% and 8.4% on semaglutide. Because glycemic burden and excess adiposity both compress healthspan, a therapy that moves both endpoints simultaneously carries implications well beyond diabetes management.

Wiley Aging CellMay 18, 2026

Fisetin Reverses Chemotherapy-Induced Vascular Aging

Fisetin, a naturally occurring senolytic compound, reversed vascular dysfunction and aortic stiffening induced by doxorubicin in mice by suppressing senescent cells and their inflammatory secretions, restoring nitric oxide availability. This demonstrates a pharmacological pathway to counter drug-induced premature vascular aging.

Peter Attia MDAug 27, 2026

GLP-1 Receptor Agonists: Metabolic and Cardiovascular Benefits

GLP-1 receptor agonists demonstrate measurable benefits across metabolic, cardiovascular, and neurological domains that extend well beyond weight reduction. These effects occur through multiple biological pathways, positioning these medications as potential tools for addressing interconnected health conditions rather than weight alone.

Longevity.TechnologyFeb 6, 2026

Rapamycin and the quiet work of immune repair

Low-dose rapamycin protects DNA in aging immune cells by reducing damage-induced cell death and senescence markers, suggesting mTOR inhibition preserves immune resilience through direct genoprotection rather than broad immunosuppression. This mechanistic clarity offers a more tractable regulatory and therapeutic pathway than the traditional anti-aging framing.

The Conversation - LongevityOct 13, 2026

NAD+ Supplements Lift Blood Levels but Not Yet Healthspan

NAD+ declines with age, and supplementation with precursors such as nicotinamide riboside and nicotinamide mononucleotide reliably raises NAD+ concentrations in blood — by roughly 50% to 140% depending on dose and compound. Whether this translates into higher NAD+ in muscle and organs, or into measurable functional benefit, remains unresolved, with human trials producing far weaker results than animal models. The gap between a shifted biomarker and an improved outcome defines the current state of the evidence.

Nature - npj AgingSep 25, 2026

High-Dose NMN Holds NAD+ Elevated for 24 Weeks in Older Adults

A 24-week randomized, double-blind, placebo-controlled trial in older adults found that high-dose nicotinamide mononucleotide supplementation produced sustained elevation of NAD⁺ levels rather than a transient spike. NAD⁺ availability declines with age and constrains mitochondrial energy output, DNA repair, and sirtuin-dependent signaling, making durable repletion a plausible lever for age-related functional decline. The trial's length and design address a central gap in prior NMN research, most of which ran for shorter periods at lower doses.

Longevity.TechnologyMar 10, 2026

Niagen Bioscience secures patent for NR injections

Niagen Bioscience secured a US patent protecting intravenous and injectable formulations of nicotinamide riboside (NR), a NAD+ precursor molecule that declines with age and cellular stress. The patent extends protection through 2044 and positions the company to dominate clinical delivery of NAD+ boosters, a market rapidly expanding across wellness clinics.

LT WireNov 10, 2026

Tirzepatide Outcomes Improve When Meal Quality Is Scored

Digbi Health reported mean weight loss of 18.4% at 12 months across 3,181 members taking tirzepatide alongside a personalized lifestyle program built on genetics, gut microbiome composition, blood biomarkers and continuous glucose data. The company compared this with three published U.S. tirzepatide cohorts reporting 12.4% to 16.5% mean loss over similar periods. Meal-quality scoring within the platform was reported to correlate with medication response, with each one-point increase in its Nutrient Density Score associated with roughly two additional percentage points of weight loss.

Wiley Aging CellApr 23, 2026

Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12

Fisetin, a plant-derived senolytic, reverses age-related endothelial dysfunction in aging mice by eliminating senescent endothelial cells and reducing the SASP factor CXCL12, which drives vascular dysfunction through oxidative stress and impaired nitric oxide production. This identifies a mechanistic pathway linking cellular senescence to cardiovascular aging and demonstrates functional recovery through targeted senolytic intervention.

Longevity.TechnologyOct 23, 2026

Senolytic Immunotherapy Trains T Cells to Clear Zombie Cells

Immorta Bio has completed preclinical work on SenoMune-0257, a nine-amino-acid synthetic peptide identified through AI screening that stimulates cytotoxic T cells to selectively clear senescent cells. The approach shifts from directly killing these cells with small molecules to restoring immune surveillance, with the aim of durable immunological memory and lower off-target toxicity. Human evaluation is anticipated before year-end, though trial design, site and regulatory status remain undisclosed.

LifeSpan.ioApr 21, 2026

Rapamycin Might Blunt Exercise Response in Humans

A randomized, placebo-controlled trial in sedentary adults aged 65-85 found that weekly rapamycin (6 mg) blunted functional gains from a 13-week exercise program, with the placebo group showing greater improvements in chair-stand performance and related measures. The drug's 62-hour half-life likely prevented adequate recovery of mTORC1 signaling between training sessions, creating a pharmacokinetic conflict with exercise adaptation.

LT WireJun 8, 2026

Mitochondrial uncoupling amplifies weight loss when paired with tirzepatide

A mitochondrial protonophore (TLC-6740) combined with tirzepatide produced an additional 4.5% weight loss over tirzepatide alone in a 24-week Phase 2a trial, with concurrent improvements in insulin sensitivity, hepatic function, and body composition. The mechanism leverages cellular energy expenditure to enhance metabolic control, relevant to understanding how pharmacological interventions can address obesity-related metabolic dysfunction at multiple tissue levels.

Nature - npj AgingApr 21, 2026

Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study

A pilot study tracking epigenetic aging markers in patients receiving semaglutide for metabolic liver disease found that GLP-1 receptor agonists may slow biological aging rates independent of weight loss alone. The finding suggests semaglutide's effects extend beyond glycemic control to influence aging-related cellular mechanisms, with implications for understanding how pharmacological interventions affect the aging process itself.

Longevity.TechnologyMar 27, 2026

Higher dose semaglutide gets fast FDA nod amid patent pressure

The FDA approved a higher-dose semaglutide formulation (Wegovy HD, 7.2 mg) in 54 days under expedited review, signaling that metabolic disease now carries national priority status alongside traditionally serious conditions. The approval demonstrates additional weight loss benefit with a comparable safety profile to lower doses, though gastrointestinal side effects remain common and new sensory symptoms warrant ongoing monitoring.

LT WireJul 31, 2026

Dual-pathway peptide therapy combines GIP antagonism with semaglutide

Antag is testing AT7687, a GIP receptor antagonist, combined with semaglutide in a Phase 2a trial for weight loss and type 2 diabetes management. The 13-week study enrolls 150 participants to evaluate body weight reduction and glycemic control as primary and secondary endpoints, with results expected in H1 2027.

Longevity.TechnologyOct 22, 2026

Injectable NAD+ Precursor Moves Into Prescription Telehealth

Niagen Bioscience has launched a pre-filled, ready-to-inject liquid form of nicotinamide riboside, dispensed through a clinician-directed telehealth platform and a licensed compounding pharmacy from 22 October. The subcutaneous route bypasses digestion, but the company has published no clinical data on the injectable format and makes no claim of superiority over oral NR. The launch signals the migration of NAD+ precursors from the supplement shelf into prescription-adjacent channels.

LT WireOct 9, 2026

Copper Peptide Skin Repair Moves Into Prescription Dosing

AgelessRx has released a prescription copper peptide (GHK-Cu) cream in two compounded strengths, 0.5% and 3%, intended to support skin repair processes that decline with age. Each prescription requires review by a licensed provider, and the company reports 99.8% purity alongside microbial and endotoxin testing; compounded formulations are not FDA-approved. The launch places a well-characterized endogenous peptide into a clinician-supervised dosing model rather than an over-the-counter cosmetic one.

Longevity.TechnologyJun 17, 2026

Creatine and Muscle: The Overlooked Longevity Foundation

Elysium Health has launched Creatine+, a three-ingredient formulation combining creatine monohydrate, HMB, and pomegranate polyphenols designed to support muscle strength, recovery, and mitochondrial function across the lifespan. As longevity science shifts focus from lifespan extension to preservation of physical function, muscle health has emerged as a critical determinant of healthy aging, reframing creatine from a sports supplement to a foundational longevity tool.

Wiley Aging CellSep 23, 2026

Rapamycin Shifts Aged Arterial Immunity Toward Regulatory T Cells

In 80- to 90-week-old Ldlr-/- mice with established atherosclerotic lesions, eight weeks of rapamycin reduced plaque macrophage content, lowered T cell numbers in vascular and lymphoid tissue, and shifted the remaining population toward central memory and regulatory phenotypes. Antigen-driven humoral responses also fell, including T follicular helper cells, germinal center B cells, plasma cells, and oxidation-specific epitope antibodies, alongside markedly reduced senescence signatures in aortic leukocytes. The work positions mTORC1 inhibition as an immune-directed rather than purely lipid-directed approach to age-related vascular disease.

LT WireJun 9, 2026

Metabolic Switch: New Compound Outperforms Tirzepatide in Obesity Model

MitoRx's MTRX31 achieved 38.4% body weight reduction and 62.2% fat loss in obese mice, exceeding tirzepatide's performance while preserving lean mass and improving metabolic markers. The compound shifted fat oxidation toward carbohydrate metabolism without reducing appetite or causing treatment habituation.

LT WireOct 19, 2026

Spermidine Powder Targets Autophagy and Daily Adherence

Oxford Healthspan has released Primeadine GF Spermidine Powder, a mixable gluten-free formulation delivering 1 mg of whole-food spermidine per serving from broken cell wall chlorella, with nobiletin from Shikuwasa citrus peel and curcumin. Spermidine is studied for its role in autophagy, the cellular recycling process that declines with age. The powder format addresses adherence by allowing the dose to be added to food or beverages rather than taken as a tablet.